sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.

[1]  J. Januzzi,et al.  Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study. , 2018, Circulation.

[2]  S. Solomon,et al.  Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE‐HF) , 2018, American heart journal.

[3]  S. Solomon,et al.  Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) , 2018, Circulation. Heart failure.

[4]  J. Januzzi,et al.  The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study , 2018, Current Heart Failure Reports.

[5]  L. Tavazzi,et al.  Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis , 2018, Circulation.

[6]  K. Anstrom,et al.  Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial , 2017, JAMA.

[7]  M. Emdin,et al.  Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. , 2017, JACC. Heart failure.

[8]  M. de Antonio,et al.  Impact of diabetes on the predictive value of heart failure biomarkers , 2016, Cardiovascular Diabetology.

[9]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[10]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[11]  A. Jaffe,et al.  Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. , 2016, Journal of cardiac failure.

[12]  M. Pfisterer,et al.  Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction , 2015, European journal of heart failure.

[13]  L. Lund,et al.  Prognostic Significance of Resting Heart Rate and Use of &bgr;-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry , 2015, Circulation. Heart failure.

[14]  J. Januzzi,et al.  The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management , 2015, Expert review of cardiovascular therapy.

[15]  J. Januzzi,et al.  ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. , 2015, The American journal of cardiology.

[16]  A. Jaffe,et al.  Soluble ST2--analytical considerations. , 2015, The American journal of cardiology.

[17]  J. Januzzi,et al.  The biology of ST2: the International ST2 Consensus Panel. , 2015, The American journal of cardiology.

[18]  T. Mueller,et al.  Soluble ST2 in heart failure. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[19]  A. Baggish,et al.  Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure , 2015, Journal of Cardiovascular Translational Research.

[20]  M. Flather,et al.  Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial , 2014, European journal of heart failure.

[21]  J. Cleland,et al.  The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. , 2014, Annals of physical and rehabilitation medicine.

[22]  B. Jankowska-Polańska,et al.  Frailty in Heart Failure , 2014, Current Heart Failure Reports.

[23]  J. Cohn,et al.  Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial , 2014, Circulation. Heart failure.

[24]  Mark Woodward,et al.  Risk prediction in patients with heart failure: a systematic review and analysis. , 2014, JACC. Heart failure.

[25]  Thomas J. Wang,et al.  Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. , 2014, JACC. Heart failure.

[26]  J. McMurray,et al.  Prognostic Effect of High-Sensitive Troponin T Assessment in Elderly Patients With Chronic Heart Failure: Results From the CORONA Trial , 2013, Circulation. Heart failure.

[27]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[28]  W. Kraus,et al.  Soluble ST2 in Ambulatory Patients With Heart Failure: Association With Functional Capacity and Long-Term Outcomes , 2013, Circulation. Heart failure.

[29]  V. Roger.  Epidemiology of Heart Failure , 2013, Circulation research.

[30]  R. D. de Boer,et al.  Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). , 2013, American heart journal.

[31]  G. Maurer,et al.  Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature , 2013, Journal of molecular and cellular cardiology.

[32]  P. Ponikowski,et al.  Iron deficiency in chronic heart failure: an international pooled analysis. , 2013, American heart journal.

[33]  Shawn A. Gregory,et al.  Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study , 2013, European journal of heart failure.

[34]  Stephen B Wheatcroft,et al.  Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology , 2013, Diabetes & vascular disease research.

[35]  T. Mueller,et al.  The Presage® ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2 , 2013, Expert review of molecular diagnostics.

[36]  J. Lupón,et al.  Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value , 2013, European journal of heart failure.

[37]  D. J. Veldhuisen,et al.  Co-morbidities in heart failure , 2014, Heart Failure Reviews.

[38]  Shawn A. Gregory,et al.  Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. , 2012, Journal of cardiac failure.

[39]  J. McMurray,et al.  Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology , 2012, European journal of heart failure.

[40]  L. Tavazzi,et al.  Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials , 2012, Circulation.

[41]  J. Lupón,et al.  Combined use of high‐sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure , 2012, European journal of heart failure.

[42]  Marco Merlo,et al.  Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. , 2011, Journal of the American College of Cardiology.

[43]  A. Wu,et al.  High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.

[44]  L. Stevens,et al.  Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  A. Jaffe,et al.  Analytical validation of a high-sensitivity cardiac troponin T assay. , 2010, Clinical chemistry.

[46]  Le-Xin Wang,et al.  The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. , 2009, Congestive heart failure.

[47]  M. Emdin,et al.  Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[48]  O. Muller,et al.  Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. , 2008, Journal of the American College of Cardiology.

[49]  Richard T. Lee,et al.  The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.

[50]  E. Braunwald,et al.  Biomarkers in heart failure. , 2008, The New England journal of medicine.